Draxis gets NRC approval for BrachySeed Pd-103

Radiopharmaceutical manufacturer DraxImage has received final approval from the U.S. Nuclear Regulatory Commission for the palladium version of its BrachySeed brachytherapy implant. The Mississauga, Ontario-based firm's implant will be marketed in the U.S. by partner Cytogen of Princeton, NJ, which expects to introduce BrachySeed Pd-103 in the fourth quarter. DraxImage will market the implant in Canada.

By AuntMinnie.com staff writers
November 13, 2001

Related Reading

Draxis revenues climb, November 8, 2001

DraxImage to make radiotherapy capsules for Bracco, August 23, 2001

Draxis posts higher revenues in Q2, August 13, 2001

DraxImage gets clearance for palladium version of BrachySeed, June 28, 2001

DraxImage gets new president, June 20, 2001

Copyright © 2001 AuntMinnie.com

Page 1 of 436
Next Page